Cancer Player Revolution Medicines Gets Bullish Rating: Here's Details
Raymond James initiated coverage on Revolution Medicines Inc RVMD, noting that the October readout of RMC-6236 was compelling compared to historical SoC. RMC-6236 is an oral, first-in-class RAS(ON) inhibitor designed to treat patients with cancers driven by a wide range of common RAS mutations.…
#raymondjames #rmc6236 #ras #daneleone #rvmd #kras #pdacnsclc